Approximately 40,000-50,000 CA/HF patients receive international device therapies like pacemakers, ICD, CRT and/or RFA.2 In Asia Pacific region, patients receive lower-than-recommended levels of pharmacological treatment.3 The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomous systems.4 In 2016, the focused pharmacologic update on the current Heart Failure Guidelines introduced the use of two newly approved drug regimens: Valsartan/sacubitril and ivabradine. These novel compounds were reported to exert additional mortality and morbidity benefits in heart failure subpopulations with reduced ejection fraction.4

References

1. Dokainish H, et al. Lancet Glob Health. 2017;5(7):e665-e672. 2Vora A, et al. Indian Heart J. 2017;69(2):229-39. 3Rajadurai J, et al. J Card Fail. 2017;23(4):327-39. 4Papadimitriou L, et al. Trends Cardiovasc Med. 2017;27(5):316-23.